Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EPS (Weighted Average and Diluted) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$1.11 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 82.32% to -$1.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.18 through Dec 2025, up 46.31% year-over-year, with the annual reading at -$8.66 for FY2025, 61.51% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.11 at bioAffinity Technologies, up from -$4.74 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.22 in Q4 2022, with the low at -$6.28 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$1.3, with a median of -$0.2 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 2315.38% in 2024, then skyrocketed 82.32% in 2025.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at $0.22 in 2022, then plummeted by 218.18% to -$0.26 in 2023, then tumbled by 2315.38% to -$6.28 in 2024, then surged by 82.32% to -$1.11 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$1.11, -$4.74, and -$0.17 for Q4 2025, Q3 2025, and Q2 2025 respectively.